Primary cutaneous mucormycosis.
Hicks
W L
WL
Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Nowels
K
K
Troxel
J
J
D000284:Administration, Oral; D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001769:Blood / Q000382:microbiology; D002442:Ceftazidime / Q000627:therapeutic use; D004926:Escherichia coli / Q000302:isolation & purification; D006689:Hodgkin Disease / Q000150:complications / Q000473:pathology; D006801:Humans; D007275:Injections, Intravenous; D007299:Insect Bites and Stings; D008297:Male; D009091:Mucormycosis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D009333:Neck / Q000503:physiopathology*; D009336:Necrosis; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D000666:Amphotericin B; D002442:Ceftazidime; D013752:Tetracycline; D012293:Rifampin